Three‐Hour Infusion of Methotrexate at 3 g/m 2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B‐Cell Lymphomas at Increased CNS Risk
- 15 March 2026
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 101 (6) , 1244-1254
Abstract
Concerns about the efficacy of high‐dose methotrexate (HD‐MTX) in preventing CNS recurrence in large B‐cell lymphomas (LBCL) are based on studies with interpretation biases and incomplete information about HD‐MTX dosing schedule and CNS events. We evaluated a pharmacokinetic‐informed, CNS‐directed HD‐MTX protocol (3 g/m 2 over 3 h, preceded by a bolus) in 336 LBCL patients achieving CMR after RCHOP or derivatives. HD‐MTX use was based on institutional risk scores. In this study, CNS risk was reassessed using updated criteria: CNS‐IPI ≥ 4, ≥ 3 extranodal sites, or involvement of testis, kidney, adrenal gland, uterus, or breast. According to these criteria, risk was low in 228 (68%) patients and high in 108 (32%); HD‐MTX was given to 20 (9%) and 49 (45%), respectively. HD‐MTX was well tolerated: 96% completed therapy. After a median follow‐up of 77 months, 13 (4%) patients experienced CNS relapse, always as isolated events. Among high‐risk patients, CNS relapse occurred in 19% (11/59) without HD‐MTX versus 0% (0/49) with HD‐MTX ( p = 0.0009); significant reductions were seen in patients with high‐risk organ involvement (32% to 0%, p = 0.002) or ≥ 3 extranodal sites (18% to 0%, p = 0.04). HD‐MTX was independently associated with improved PFS and OS in high‐risk patients, likely due to reduced CNS relapses (0% vs. 19%; p = 0.0009), whereas rates of unrelated deaths (8% vs. 15%; p = 0.26) and systemic relapses (18% vs. 22%; p = 0.81) were similar. In conclusion, HD‐MTX, administered via a pharmacokinetic‐informed, CNS‐directed schedule, with or without intrathecal chemotherapy, significantly reduces CNS relapses and improves outcomes in high‐risk LBCL patients in CMR. Trial Registration: ClinicalTrials.gov Identifier: NCT07181785.Keywords
Funding Information
- Roche Italia
This publication has 32 references indexed in Scilit:
- Chimeric antigen receptor T‐cell therapy in secondary central nervous system lymphoma: A multicenter analysisAmerican Journal of Hematology, 2024
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsLeukemia, 2022
- Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphomaAmerican Journal of Hematology, 2021
- MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trialThe Lancet Haematology, 2021
- Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trialAnnals of Oncology, 2020
- Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysisHematological Oncology, 2019
- The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapyEuropean Journal of Cancer, 2017
- A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphomaBritish Journal of Cancer, 2014
- Risk of CNS dissemination in extranodal lymphomasThe Lancet Oncology, 2014
- Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphomaCancer, 2010